GALNT18

Across TCGA pan-cancer cohorts, GALNT18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GALNT18 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GALNT18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALNT18 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, LSCC, and GBM are the cancer types where GALNT18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.620	0.963	.038	4	view →
LSCC	DFS	Median	II,III,IV	0.183	0.793	.008	4	view →
GBM	OS	Median	All	0.410	0.644	.038	2	view →
LUAD	OS	Median	All	0.577	0.817	.027	1	view →
CCRCC	OS	Median	All	1.000	0.914	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GALNT18–HNSC (DFS)

Open the HNSC breakdown →